Skip to search formSkip to main contentSkip to account menu

Anti-OX40 Monoclonal Antibody GSK3174998

Known as: GSK3174998 
An agonistic humanized immunoglobulin G1 (IgG1) monoclonal antibody against the cell surface receptor OX40 (CD134; TNFRSF4), with potential immune… 
National Institutes of Health

Related topics

Related topics

4 relations
Antibody-Dependent Cellular CytotoxicityB-LymphocytesCytotoxic T-Lymphocytesantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.
TPS3107Background: OX40 (CD134) is a potent costimulatory tumor necrosis factor receptor expressed on activated CD4+ and CD8+ T… 
2016
2016
Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)
Background: OX40 (CD134) belongs to the tumor necrosis factor receptor (TNFR) family, and transduces a costimulatory signal… 
2016
2016
Abstract 4864: Engaging the immune system with GSK3174998, a potent anti-OX40 agonist antibody
Introduction: GSK3174998, a humanized IgG1 agonistic anti-OX40 monoclonal antibody (mAb) identified in collaboration between GSK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)